Skip to main content
Premium Trial:

Request an Annual Quote

Note to Readers: Apr 12, 2005


Starting with this issue, Inside Bioassays has changed its name to Cell-Based Assay News to more accurately reflect the scope of its coverage — which, as the new tagline suggests, is high-throughput and high-content cell-based assays for drug discovery and functional genomics.

Readers of Inside Bioassays will have already noticed that since mid-last year we had begun to focus more intently on cell-based assays, an editorial decision that was made around the time that a slew of publicly traded companies began to invest heavily in cell-based assay technology. In addition, pharma, biotech, and academia alike have shifted their focus perceptibly to cell-based assay technologies both for drug discovery and basic biological research.

Lastly, Cell-Based Assay News acknowledges the continued importance of biochemical assays in biology, and will continue to cover news in this area when applicable. However, the cellular-analysis space better fits parent publication GenomeWeb News’ continued mission to cover the emerging field of systems biology, from gene to phenotype. We hope our readers also see these developing trends, and we pledge to continue to bring you the latest news every week in cell-based assay technology.

— Ben Butkus, Cell-Based Assay News editor

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.